A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. Recent Developments Separation from Former Parent In January 2024, Inhibrx, Inc., or the Former Parent, announced its intent to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. On May 29, 2024, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of common stock of the Company, or the Distribution.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | - |
| Net Income | -155M | 1.7B | -241M |
| EPS | $-11.40 | $112.62 | $-20.48 |
| Free Cash Flow | -143M | -197M | -198M |
| ROIC | -68.6% | -183.4% | -96.4% |
| Gross Margin | - | - | - |
| Debt/Equity | 2.71 | 0.00 | 4.76 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -154M | -331M | -219M |
| Operating Margin | 0.0% | - | - |
| ROE | -421.1% | 1905.9% | -554.8% |
| Shares Outstanding | 15M | 15M | 12M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -219M | -331M | -154M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -241M | 1.7B | -155M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -96.4% | -183.4% | -68.6% |
| ROE | -554.8% | 1905.9% | -421.1% |
| ROA | -78.4% | 690.7% | -87.4% |
| Cash Flow | |||
| Op. Cash Flow | -193M | -194M | -143M |
| Free Cash Flow | -198M | -197M | -143M |
| Owner Earnings | -219M | -255M | -204M |
| CapEx | 4.6M | 2.6M | 0 |
| Maint. CapEx | 1.2M | 2.3M | 2.3M |
| Growth CapEx | 3.4M | 312K | 0 |
| D&A | 1.2M | 2.3M | 2.3M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 25M | 59M | 59M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | -71M | -153M | -53M |
| Cash & Equiv. | N/A | N/A | 153M |
| Long-Term Debt | 207M | 0 | N/A |
| Debt/Equity | 4.76 | 0.00 | 2.71 |
| Interest Coverage | -6.9 | -24.6 | -24.6 |
| Equity | 44M | 134M | 37M |
| Total Assets | 308M | 181M | 177M |
| Total Liabilities | 264M | 47M | 141M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -614M | -106M | -106M |
| Working Capital | 239M | 120M | 120M |
| Current Assets | 295M | 160M | 160M |
| Current Liabilities | 56M | 41M | 41M |
| Per Share Data | |||
| EPS | -20.48 | 112.62 | -11.40 |
| Owner EPS | -18.61 | -17.03 | -14.04 |
| Book Value | 3.69 | 8.91 | 2.53 |
| Cash Flow/Share | -16.40 | -12.97 | -10.51 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 11.8M | 15.0M | 14.5M |
| Valuation | |||
| P/E Ratio | N/A | 0.1 | -7.3 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 1.7 | 32.9 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -87.6% | -11.9% |
| Market Cap | N/A | 225M | 1.2B |
| Avg. Price | N/A | 14.78 | 83.19 |
| Year-End Price | N/A | 15.01 | 83.19 |
Inhibrx Biosciences, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -2.5%.
Inhibrx Biosciences, Inc. (INBX) has a 5-year average return on invested capital (ROIC) of -139.9%. This is below average and may indicate limited pricing power.
Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.2B. It is classified as a small-cap stock.
Inhibrx Biosciences, Inc. (INBX) does not currently pay a regular dividend.
Inhibrx Biosciences, Inc. (INBX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Inhibrx Biosciences, Inc. (INBX) generated $-197 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Inhibrx Biosciences, Inc. (INBX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Inhibrx Biosciences, Inc. (INBX) reported earnings per share (EPS) of $112.62 in its most recent fiscal year.
Inhibrx Biosciences, Inc. (INBX) has a return on equity (ROE) of 1905.9%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 2 years of financial data for Inhibrx Biosciences, Inc. (INBX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Inhibrx Biosciences, Inc. (INBX) has a book value per share of $8.91, based on its most recent annual SEC filing.